Researchers Say Ebola Vaccine Trials Being Fast-tracked

Researchers have revealed that safety trials on an Ebola vaccine are being fast-tracked, meaning it could be given to healthy volunteers as early as September.

The vaccine will be given to volunteers in Britain, the Gambia and Mali in a bid to tackle the spread of an epidemic which has spread across west Africa, killing 1,552 so far.

Ebola Virus Disease | Ebola Hemorrhagic Fever: Cause Symptoms Diagnosis Treatment
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have identified five types of Ebola or Ebola hemorrhagic fever virus.

Researchers hope the trials could finish by the end of 2014.

If they are successful, the vaccine could then be given to people infected with Ebola, which is spread through bodily fluids.

The move was announced by pharmaceuticals giant GlaxoSmithKline -- which is developing the vaccine with the US National Institutes of Health (NIH) -- and London-based medical charity Wellcome Trust, which is contributing to a grant to pay for the trials.

Quiz on Ebola
Why is the deadly Ebola virus outbreak making the health experts hit the panic button? Find out from this quiz.

"A candidate Ebola vaccine could be given to healthy volunteers in the UK, the Gambia and Mali as early as September, as part of a series of safety trials of potential vaccines," the statement said.

A total of 3,062 cases have so far been reported but the World Health Organization warned Thursday that the caseload could eventually exceed 20,000.

Researchers Release Genome Sequences of Ebola Virus With the Hope of Accelerating Hunt for Treatments
Around 99 sequenced genomes of the deadly Ebola virus have been released by scientists tracking the spread of the outbreak.

The trials, which still need ethical and regulatory approval, will be funded by a £2.8 million (3.5 million euro, $4.6 million) grant from the Wellcome Trust, Britain's Medical Research Council (MRC) and the UK Department for International Development (DFID).

The Oxford study will involve 60 healthy volunteers, while those in the Gambia and Mali will each involve 40.

World Food Program to Boost Operations in West Africa Following Ebola Outbreak
The World Food Program revealed that it plans to step up its emergency aid operations in the area.

This will also allow GSK to make some 10,000 extra doses of the vaccine so that if the trials are successful, it could be made available to the WHO quickly.

Safety tests of the vaccine will take place at Oxford University alongside a US trial run by the National Institute of Allergy and Infectious Diseases (NIAID).

Source-AFP